about
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VIEnzyme replacement therapy with galsulfase for mucopolysaccharidosis type VIReview and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disordersAnaesthesia and airway management in mucopolysaccharidosis.Respiratory and sleep disorders in mucopolysaccharidosisSensory-motor behavioral characterization of an animal model of Maroteaux-Lamy syndrome (or Mucopolysaccharidosis VI).Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfataseMucopolysaccharidosis VI.Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase.Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment.Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VI.Illness perception and clinical treatment experiences in patients with M. Maroteaux-Lamy (mucopolysaccharidosis type VI) and a Turkish migration background in Germany.Growth Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome)Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI.Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and managementA review of gene therapy in canine and feline models of lysosomal storage disorders.Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VIAnesthesia in a child with Maroteaux-Lamy syndrome undergoing mitral valve replacementDiagnostic and treatment strategies in mucopolysaccharidosis VI.Combined Enzyme Replacement Therapy and Hematopoietic Stem Cell Transplantation in Mucopolysacharidosis Type VI.Molecular findings of Colombian patients with type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome).Long-term cognitive follow-up in children treated for Maroteaux-Lamy syndrome.Ethical and economic considerations of rare diseases in ethnic minorities: the case of mucopolysaccharidosis VI in Colombia.Haploidentical stem cell transplantation in two children with mucopolysaccharidosis VI: clinical and biochemical outcome.Management of otolaryngological manifestations in mucopolysaccharidoses: our experience.Energy expenditure during gait in patients with mucopolysaccharidosis.Cardiac disease as the presenting feature of mucopolysaccharidosis type IIIA: A case report.Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux-Lamy syndrome): under-recognized and challenging to diagnose.Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI.Orthopaedic aspects of mucopolysaccharidoses.Therapy for the mucopolysaccharidoses.Genetics and metabolic cardiomyopathies.Current and potential therapeutic strategies for mucopolysaccharidoses.Epidemiology of mucopolysaccharidoses.A clinical multicenter study of orofacial features in 26 brazilian patients with different types of mucopolysaccharidosis.Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: Results from a single-center case series study.Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up.Combined mucopolysaccharidosis type VI and congenital adrenal hyperplasia in a child: Anesthetic considerations.Clinical Evolution After Enzyme Replacement Therapy in Twins with the Severe Form of Maroteaux-Lamy Syndrome
P2860
Q24186047-EC803412-FDAF-4F21-9341-E55C1C73E992Q24198820-CC5EC1F6-C526-4485-B526-99D798499C7CQ26771677-74E27007-6FCD-46F6-A5AD-24426351B751Q26996429-0B7EA68E-270B-41F1-86D3-DC707DB3FCF4Q30457547-4BC03F81-C4DD-4FB3-A5AD-5073EAF378A7Q30563980-2B49C3B4-61BA-43B0-B950-19BD71436DE8Q33630446-0408264B-1B90-477A-88CA-37166790B24EQ33688165-E08042CB-BBA0-41CD-B402-B71F6C73D6FAQ33863356-CF1E24AC-945A-4D38-A8ED-59D2D58B2DA2Q33995906-B7CFD093-BBBE-4C98-9FCA-C6B0AE22D68BQ34562817-F63B5B50-CB6C-41C1-8A91-73BC7E60175DQ34657166-ABA0710C-7B0A-4CA0-A980-46954558D8C5Q34796031-4EB0EAA9-54DA-476B-8F3C-6435F6E6FF23Q35183098-0E109816-75F5-4C70-B0D3-BA68470B13E0Q35570893-EFD29A65-48EC-40E0-A841-63D40A29BA9AQ35587435-12CF8E90-34DE-47F8-8A54-48B1EAD7A8ADQ35894676-668E82B5-3E15-4131-8F17-A2CC92DB71A5Q36009130-E426164D-2646-4907-913C-B6D45F32EB3BQ36017334-57BC242C-3EC8-4D1D-B2A5-5419D0C7A271Q36253221-29BAFEE0-A78E-4486-A1EA-F4A61CD24D79Q36433293-561BDC0E-B992-4B62-AB57-E3037F04DC7BQ36521405-09189168-022E-40FF-9C5E-6BB7B1665A20Q36582221-55052CA9-2488-4944-A7D4-78885E7B9AAFQ36637927-B8FBE4D7-B365-4CB9-9870-27EA1ACCD3A0Q37154973-2C75D313-AE85-47A5-B1FC-6D44F073B47BQ37173777-D15D2829-035B-48B5-BE2D-5B5F257C401DQ37389527-FF6C10F1-FFC1-4BA3-9D79-BF43FB9295F4Q37434238-7607C017-AA2F-4DED-AEBB-B11171B71493Q37515209-13131C67-6F19-41B2-AA9C-F91A4481FABCQ37686034-BB2C6A13-D0A6-4D90-B99D-22ADBFED8E9CQ37972587-89BFD33E-DDB6-4B50-BEF1-D70E5804FC26Q37972592-74DB79BF-C108-4105-B4B6-5AA9DFC79F14Q38039376-28C979F1-78E7-4A45-B93D-E736B166DE55Q38194635-862F82AD-2C02-492F-B6A8-0A0677341A92Q38735623-38F57C22-A54F-42B2-8308-43E1D1FF11BCQ39177247-6D6B7F64-E045-480C-9A3B-AFDC6787242BQ41700161-E591D97C-C352-43B8-B6BF-24983329A7CEQ42128578-84C78152-201F-4FB7-959A-E36DB231DCB0Q42258182-F7FE1CEE-124C-4D57-B8ED-4ABE0C9A6CC1Q42368422-661E0540-D675-4898-B61C-2E5FC7B92162
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Management guidelines for mucopolysaccharidosis VI.
@en
type
label
Management guidelines for mucopolysaccharidosis VI.
@en
prefLabel
Management guidelines for mucopolysaccharidosis VI.
@en
P2093
P356
P1433
P1476
Management guidelines for mucopolysaccharidosis VI.
@en
P2093
James E Wraith
Paul Harmatz
Roberto Giugliani
P304
P356
10.1542/PEDS.2006-2184
P407
P577
2007-08-01T00:00:00Z